8-K: Fortress Biotech Reports Strong 2025 Results, Key Approvals

Fortress Biotech announced its full-year 2025 financial results and corporate highlights, including FDA approvals, significant asset monetizations, and advancements in its clinical pipeline.

Summary

• The FDA approved ZYCUBO (copper histidinate) for the treatment of Menkes disease in pediatric patients in January 2026.
• Fortress subsidiary Cyprium Therapeutics sold a Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205 million in March 2026.
• Cyprium is eligible to receive tiered royalties and up to approximately $128 million in aggregate sales milestones from Sentynl Therapeutics for ZYCUBO.
• Fortress expects to receive an aggregate of at least $100 million from Cyprium through potential future dividends and intercompany agreements.
• Fortress subsidiary Checkpoint Therapeutics was acquired by Sun Pharmaceutical Industries, Inc. in May 2025 for an aggregate upfront payment totaling ~$355 million and ~$60 million in a contingent value right (CVR).
• Fortress received ~$28 million upfront from the Checkpoint acquisition and is eligible for up to an additional $4.8 million CVR payment and a 2.5% royalty on future net sales of UNLOXCYT (cosibelimab-ipdl).
• UNLOXCYT was approved by the FDA in December 2024 to treat metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) and was commercially launched in January 2026.
• Avenue Therapeutics' subsidiary Baergic Bio, Inc. was acquired by Axsome Therapeutics in November 2025, with Avenue eligible for up to $79 million in potential sales milestones and tiered mid-to-high single-digit royalties.
• Crystalys Therapeutics, in which Fortress's subsidiary Urica Therapeutics holds an equity position, announced a $205 million Series A financing in the third quarter of 2025 to support two global Phase 3 clinical studies for dotinurad for gout.
• Urica is eligible to receive a 3% royalty on future net sales of dotinurad.
• Journey Medical Corporation commercially launched Emrosi (40mg Minocycline Hydrochloride Modified-Release Capsules) for inflammatory lesions of rosacea at the end of March 2025, following FDA approval in November 2024.
• Journey Medical reported net product revenues of $61.2 million for full-year 2025, compared to $55.1 million for full-year 2024.
• Dotinurad entered Phase 3 development in October 2025, with the first patients dosed in two randomized, double-blind, multicenter global trials for gout.
• In July 2025, AstraZeneca announced that anselamimab (CAEL-101) did not achieve statistical significance for the primary endpoint in its Phase III CARES clinical program for Mayo stages IIIa and IIIb AL amyloidosis patients, but showed clinically meaningful improvement in a prespecified subgroup.
• Full results from two Phase 3 clinical trials evaluating Emrosi for moderate-to-severe papulopustular rosacea were published in JAMA Dermatology in March 2025, demonstrating efficacy, safety, and tolerability.
• Results from a Phase 1 clinical trial for Emrosi, assessing its impact on microflora, were published in the Journal of Drugs in Dermatology in December 2025, indicating no detectable effects on skin, GI tract, or vaginal microflora.
• The first patient was dosed in a Phase 2 clinical trial for Triplex, a cytomegalovirus (CMV) vaccine, in January 2025.
• In March 2026, Fortress made aggregate prepayments on its loan with Oaktree, reducing the outstanding principal balance to $15.0 million.
• Avenue Therapeutics licensed ATX-04 (clenbuterol) for Pompe disease from Duke University in February 2026 and anticipates meeting with the FDA in 2026 to discuss a potential single pivotal trial.
• Fortress consolidated cash and cash equivalents totaled $79.4 million as of December 31, 2025, an increase from $57.3 million as of December 31, 2024.
• Consolidated net revenue totaled $63.3 million for full-year 2025, up from $57.7 million for full-year 2024.
• Consolidated research and development expenses decreased to $11.9 million for full-year 2025, from $56.9 million for full-year 2024.
• Consolidated selling, general and administrative costs were $96.4 million for full-year 2025, compared to $87.7 million for full-year 2024.
• Consolidated net loss attributable to common stockholders significantly improved to $(1.9) million, or $(0.07) per share, for full-year 2025, compared to $(55.9) million, or $(2.69) per share, for full-year 2024.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive report, driven by multiple successful asset monetizations, significant regulatory approvals, and a substantial improvement in financial performance, particularly the dramatic reduction in net loss and increased cash position.

Positives

• FDA approval of ZYCUBO for Menkes disease in January 2026.
• Sale of a Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million gross proceeds by Cyprium Therapeutics.
• Eligibility for tiered royalties and up to $128 million in sales milestones for ZYCUBO from Sentynl Therapeutics.
• Fortress expects to receive at least $100 million from Cyprium through future dividends and intercompany agreements.
• Acquisition of Checkpoint Therapeutics by Sun Pharma, generating ~$28 million upfront for Fortress and potential for an additional $4.8 million CVR and a 2.5% royalty on UNLOXCYT sales.
• FDA approval of UNLOXCYT in December 2024 and its commercial launch in January 2026.
• Acquisition of Avenue Therapeutics' subsidiary Baergic Bio by Axsome Therapeutics, with Avenue eligible for up to $79 million in sales milestones and tiered mid-to-high single-digit royalties.
• Crystalys Therapeutics' $205 million Series A financing to advance dotinurad into Phase 3, with Urica (Fortress subsidiary) holding equity and a 3% royalty.
• Journey Medical's net product revenues increased to $61.2 million in 2025 from $55.1 million in 2024.
• Significant reduction in consolidated net loss attributable to common stockholders from $(55.9) million in 2024 to $(1.9) million in 2025.
• Increase in consolidated cash and cash equivalents to $79.4 million in 2025 from $57.3 million in 2024.
• Reduction of outstanding principal balance on the Oaktree loan to $15.0 million through prepayments.
• Progression of dotinurad into Phase 3 development for gout.
• Positive Phase 3 data for Emrosi published in peer-reviewed journals, demonstrating efficacy, safety, and tolerability.
• Licensing of ATX-04 for Pompe disease with human proof-of-concept data and anticipation of a potential single pivotal trial discussion with the FDA in 2026.

Negatives

• Anselamimab (CAEL-101) Phase 3 CARES program did not achieve statistical significance for its primary endpoint in Mayo stages IIIa and IIIb AL amyloidosis patients.
• Consolidated selling, general and administrative costs increased to $96.4 million for full-year 2025, compared to $87.7 million for full-year 2024.

Risks

• Risks relating to the company's growth strategy, financing, and strategic agreements and relationships.
• Need for substantial additional funds and uncertainties relating to financings.
• Uncertainty related to the timing and amounts expected to be realized from future milestone, contingent value right, royalty or similar future revenue streams, if at all.
• Ability to identify, acquire, close and integrate product candidates successfully and on a timely basis.
• Ability to attract, integrate and retain key personnel.
• The early stage of product candidates under development.
• The results of research and development activities.
• Uncertainties relating to preclinical and clinical testing.
• Ability to obtain regulatory approval for products under development.
• Ability to successfully commercialize products for which regulatory approval is received or receive royalties or other distributions from third parties.
• Ability to secure and maintain third-party manufacturing, marketing and distribution of products and product candidates.
• Government regulation.
• Patent and intellectual property matters.
• Competition.

Future Outlook

Fortress expects to receive an aggregate of at least $100 million from Cyprium pursuant to potential future dividends and intercompany agreements. Avenue anticipates meeting with the FDA in 2026 to discuss and align on the design of a potential single pivotal trial for ATX-04 for Pompe disease. AstraZeneca plans to submit the prespecified subgroup analysis from the CARES trials for anselamimab to regulatory authorities.

Management Comments

• "2025 and early 2026 reflect disciplined execution across our portfolio, including monetizing assets, achieving key regulatory approvals and advancing high-value clinical programs."
• "The acquisition of Checkpoint Therapeutics, Inc. by Sun Pharma generated meaningful upfront capital and established a long-term royalty stream from UNLOXCYT, highlighting the strength of our business model."
• "The FDA approval of ZYCUBO for Menkes disease, followed by the recent sale of the Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million by our majority-owned subsidiary Cyprium Therapeutics, Inc., demonstrates our continued ability to advance our portfolio toward value-generating approvals and corporate transactions."
• "Additionally, the progression of dotinurad into Phase 3 by Crystalys Therapeutics, supported by its Series A $205 million financing, further validates our strategy of building diversified revenue streams and creating long-term shareholder value."

Industry Context

StockSavvy.ai notes that Fortress Biotech's strategy of acquiring and advancing assets through a network of subsidiaries and partners, coupled with monetizing successful programs (like Checkpoint and Cyprium's PRV), aligns with a diversified, de-risked approach common in the biopharmaceutical industry, particularly for companies seeking to generate multiple revenue streams beyond direct product sales. The focus on rare diseases (Menkes, Pompe) and oncology (cSCC) reflects high-value therapeutic areas with significant unmet needs and potential for premium pricing and expedited regulatory pathways (e.g., PRV).

Comparison to Industry Standards

• The sale of a Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million is a significant monetization event. For comparison, recent PRV sales have ranged from $80 million to over $300 million, with $205 million falling within a strong mid-to-high range, indicating robust market demand for such vouchers.
• The acquisition of Checkpoint Therapeutics by Sun Pharma for an aggregate upfront payment of ~$355 million, plus CVRs and royalties, is comparable to other mid-sized biotech acquisitions, reflecting the value placed on approved oncology assets like UNLOXCYT (cosibelimab-ipdl) in the competitive immuno-oncology space.
• Crystalys Therapeutics' $205 million Series A financing for dotinurad's Phase 3 gout program is a substantial raise, indicating strong investor confidence in the drug's potential in a large market, comparable to significant early-stage funding rounds for promising late-stage clinical assets.

Related Party Transactions

• Fortress expects to receive an aggregate of at least $100 million from Cyprium (a majority-owned subsidiary) pursuant to potential future dividends and intercompany agreements, including amounts owed by Cyprium to Fortress through intercompany debt, interest and accrued expenses.

Stakeholder Impact

• Shareholders: Positive impact due to significant asset monetizations, regulatory approvals, reduced net loss, increased cash, and potential for future royalty and milestone payments, enhancing long-term value.
• Employees: Continued operations and advancements across subsidiaries suggest stability and potential growth opportunities.
• Customers/Patients: Availability of newly approved drugs like ZYCUBO (Menkes disease) and UNLOXCYT (cSCC), and progression of other candidates like dotinurad (gout) and ATX-04 (Pompe disease), offers new treatment options.
• Creditors: Prepayment on Oaktree loan reduces outstanding principal balance, indicating improved financial health and reduced credit risk.

Next Steps

• Sentynl Therapeutics to continue commercial launch of ZYCUBO for Menkes disease.
• Sun Pharma to continue commercial launch of UNLOXCYT for cSCC.
• Crystalys Therapeutics to continue two global Phase 3 clinical studies for dotinurad for gout.
• AstraZeneca plans to submit prespecified subgroup analysis from the CARES trials for anselamimab to regulatory authorities.
• Avenue anticipates meeting with the FDA in 2026 to discuss and align on the design of a potential single pivotal trial for ATX-04 for Pompe disease.

Key Dates

Recommendation

The filing demonstrates exceptional execution on Fortress Biotech's strategy, marked by multiple high-value asset monetizations (PRV sale, Checkpoint acquisition), significant regulatory approvals (ZYCUBO, UNLOXCYT), and substantial financial improvement, including a dramatic reduction in net loss and a strengthened cash position. These achievements de-risk the portfolio, establish long-term royalty streams, and validate the company's business model, making it a compelling investment opportunity.

Keywords

Biotech, Pharmaceuticals, FDA Approval, Menkes Disease, ZYCUBO, PRV, Priority Review Voucher, Oncology, cSCC, UNLOXCYT, Cosibelimab, Gout, Dotinurad, Rosacea, Emrosi, Pompe Disease, ATX-04, Clinical Trials, Asset Monetization, Royalties, Financial Results, Fortress Biotech